Navigation Links
SURPASS Announces Two Strategic Hires in Silicon Valley Facility and Launch of Social Media Accounts

OSCEOLA, Wis. and MOUNTAIN VIEW, Calif., July 17, 2014 /PRNewswire-iReach/ -- Surpass, Inc. ("Surpass"), a recognized leader in translational preclinical research, today announced the addition of David Craig, a veteran preclinical scientist and expert veterinary interventionalist, and Benigno Mills, a veterinary surgical and interventional specialist, to the Surpass-Silicon Valley Team. In addition, to better serve our clients, we are pleased to announce that Surpass has launched social media accounts on Twitter, Facebook and Google+ to supplement the existing account on Linked In.

Photo -

"Surpass is an integrated medical innovation partner for clients in the life-sciences community.  These recent strategic hires are evidence of Surpass' commitment to meet our clients' ever-changing needs - rounding out the Scientific and Veterinary Research Team at our West Coast site. With budgets getting tighter and timelines shorter, clients are looking for their CRO partners to do more. They want expertise in study conduct, execution, and reporting while offering flexibility in a compliant environment. The Surpass team offers customized service at our Midwest and West Coast facilities with expert professionals in surgical and interventional services," said Dr. Tim Pelura, President and CEO of Surpass.

David Craig, BS, Director of Operations and Interventional Services, comes to Surpass with more than 17 years of preclinical research experience, working at multiple domestic and international CROs and large medical device and pharmaceutical companies. Benigno Mills, BS, SRS, Interventional and Surgical Specialist, comes with more than five years of preclinical experience at a local contract research organization.

In addition to the recent hires, Surpass is pleased to announce the expansion of our social media platform to include Twitter, Facebook and Google+. "The world of corporate communications has changed.  As a valued partner, we want to connect with our clients where they are, on Twitter, Facebook and Google Plus in addition to Linked In. We want to provide value and insight for making their jobs easier," said Dr. Pelura.

About Surpass

Our innovative approach to preclinical research goes beyond the ordinary. We're changing the rules for a better way to get from concept to reality.

Surpass is a trusted contract research organization (CRO) with extensive experience conducting medical device, pharmaceutical, biotech and combination product studies with specialized expertise in surgical and interventional procedures. Our testing services include early feasibility, product development, GLP, and physician/clinical training studies. At Surpass, we provide insightful solutions and support every step of the way, offering expert advice and the level of comprehensive support needed to make your study successful – the first time.

Surpass' breadth of case experience in preclinical studies includes feasibility and safety assessments of ablation systems, vascular grafts, orthopedic prostheses, stents, closure devices, valves, infusion pumps, drug coated balloons, neurostimulators, pharmaceuticals, biologics, imaging systems, cardiac assist devices, and more. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful. Contact Surpass today at (651) 433-4277 (Greater Twin Cities) or (650) 477-8267 (Silicon Valley).

Visit for more information. Connect with Surpass, Inc. on Linked In, Twitter, Facebook, and Google+.

Media Contact: Denise Forkey, Surpass, Inc., 650-938-2101,

News distributed by PR Newswire iReach:

SOURCE Surpass, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. JCB Laboratories Debuts High Tech Monitoring System That Will Further Enhance Patient Safety, Surpass Compounding Pharmacy Standards
2. French Man Surpasses Two Years of Support with SynCardia Total Artificial Heart
3. SynCardia Total Artificial Heart Surpasses 100th Implant of 2013
4. Global Ubiquitin Proteasome Research and Development Market to Surpass $5.5 Billion by 2018: BCC Research
5. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
6. University of Oklahoma Housing and Food Likely to Surpass Budget, My Cleaning Products Recommends Pest Control Products That Could the Department's Spending in Half
7. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
8. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
9. Accuray Surpasses 600 Installations Globally
10. Pure Energy Group Announces Affiliation with American Biogas Council
11. Roka Bioscience Announces Pricing of Initial Public Offering
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):